Challenges in implementing opioid agonist therapy in Lebanon: a qualitative study from a user's perspective.

about

Challenges in implementing opioid agonist therapy in Lebanon: a qualitative study from a user's perspective.

Item

http://www.wikidata.org/entity/Q52577389

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Challenges in implementing opi ...... udy from a user's perspective.

@en

Challenges in implementing opi ...... udy from a user's perspective.

@nl

type

Item

label

Challenges in implementing opi ...... udy from a user's perspective.

@en

Challenges in implementing opi ...... udy from a user's perspective.

@nl

prefLabel

Challenges in implementing opi ...... udy from a user's perspective.

@en

Challenges in implementing opi ...... udy from a user's perspective.

@nl

P1476

Challenges in implementing opi ...... udy from a user's perspective.

@en

P2093

Ali Ghaddar

http://www.w3.org/2001/XMLSchema#string

Sanaa Khandaqji

http://www.w3.org/2001/XMLSchema#string

Zeinab Abbass

http://www.w3.org/2001/XMLSchema#string

P2860

The current status of opioid maintenance treatment in France: a survey of physicians, patients, and out-of-treatment opioid users.

Patient satisfaction and sustained outcomes of drug abuse treatment.

Practical considerations for the clinical use of buprenorphine.

The profile of injection drug users in Chennai, India: identification of risk behaviours and implications for interventions.

Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.

The role of patient satisfaction in methadone treatment

A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.

Comparing overdose mortality associated with methadone and buprenorphine treatment.

Clinical pharmacology of buprenorphine: ceiling effects at high doses.

Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users.

P2888

s13011-018-0151-8

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13011-018-0151-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1103469543

http://www.w3.org/2001/XMLSchema#string

P698

29673369

http://www.w3.org/2001/XMLSchema#string

P921

Lebanon

P932

5909215

http://www.w3.org/2001/XMLSchema#string